



Discover greater **prognostic power**

Cardiac PET with Flyrcado delivers higher diagnostic certainty vs. SPECT for CAD cases¹

For patients with known or suspected CAD, SPECT isn't always good enough.²⁻⁴ Cardiac PET MPI provides enhanced clarity for adult patients with^{4,5}:

- ✓ High body mass index (>30)
- ✓ Large or dense breast tissue
- ✓ Smaller hearts
- ✓ Multivessel disease
- ✓ Challenging conditions like diabetes or chronic kidney disease



Unclear images have a negative downstream impact on patients and the entire health system, with increased possibility of^{1,6,7}:

Repeat testing

Additional procedures to clarify diagnosis

Missed disease

Cardiac PET delivers clarity to patients and value for the health system¹



Diagnostic confidence

85% diagnostic certainty with PET using Flyrcado compared to 52% with SPECT ($P < 0.0001$).¹



May reduce downstream testing

Patients who underwent SPECT MPI had significantly more downstream testing in the following 3 months compared to those who underwent PET MPI (8.9% vs 6.4%, $P = 0.003$).⁷

PET = Positron emission tomography; SPECT = Single photon emission computed tomography;
CAD = Coronary artery disease; MPI = Myocardial perfusion imaging.

Flyrcado makes cardiac PET the clear choice

Regional radiopharmacy delivery

No need for on-site generator/
cyclotron means greater accessibility.^{3,8}

High spatial resolution

Greater clarity than SPECT for
more confident image interpretation.⁸

Shorter procedure time

Shorter protocol times than SPECT
create procedural flexibility.^{3,9}

Allows for exercise stress testing

The 109-minute half-life
allows for either exercise or
pharmacologic stress testing.^{3,9}

Lower radiation exposure

About half the radiation exposure
versus SPECT.¹

IMPORTANT SAFETY INFORMATION

FLYRCADO™ (flurpiridaz F 18) injection, for intravenous use

Indications and Usage

FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.

Contraindications

None

Radiation Risks

FLYRCADO contributes to cumulative radiation exposure, which is associated with an increased risk of cancer. Handle safely to minimize exposure for patients and staff. Advise patients to hydrate before and after administration and to void frequently.

Adverse Reactions

Most common adverse reactions (≥2%) include dyspnea, headache, angina pectoris, chest pain, fatigue, ST-segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.

Use in Specific Populations

Pregnancy: No human data are available. Counsel patients about potential fetal risks related to radiation and ethanol exposure (contains up to 337 mg anhydrous ethanol).

Lactation: Advise women to pump and discard breast milk for at least 8 hours after administration.

Pediatric Use: Safety and effectiveness have not been established.

To report SUSPECTED ADVERSE REACTIONS, contact GE Healthcare at 800-654-0118 (option 2, then option 1) or by e-mail at GPV.drugsafety@gehealthcare.com or FDA at 800-FDA-1088 or www.fda.gov/medwatch.



Scan to watch the *On the Fly* video with April Mann

Learn how getting the right answer
the first time reduces negative impact
on patients and health systems.

References: 1. Maddahi J, Agostini D, Bateman TM, et al. Flurpiridaz F-18 PET myocardial perfusion imaging in patients with suspected coronary artery disease. *J Am Coll Cardiol.* 2023;82(16):1598-1610. 2. Li DL, Kronenberg MW. Myocardial perfusion and viability imaging in coronary artery disease: clinical value in diagnosis, prognosis, and therapeutic guidance. *Am J Med.* 2021;134(8):968-975. 3. Patel KK, Singh A, Bateman TM. The potential of F-18 flurpiridaz PET/CT myocardial perfusion imaging for precision imaging. *Curr Cardiol Rep.* 2022;24(8):987-994. 4. Schindler TH, Bateman TM, Berman DS, et al. Appropriate use criteria for PET myocardial perfusion imaging. *J Nucl Med.* 2020;61(8):1221-1265. 5. Bateman TM, Dilsizian V, Beanlands RS, DePuey EG, Heller GV, Wolinsky DA. American Society of Nuclear Cardiology and Society of Nuclear Medicine and Molecular Imaging joint position statement on the clinical indications for myocardial perfusion PET. *J Nucl Med.* 2016;57(10):1654-1656. 6. Pelletier-Galarneau M, Cabra A, Szabo E, et al. Real-world evidence study on the impact of SPECT MPI, PET MPI, cCTA and stress echocardiography on downstream healthcare utilization in patients with coronary artery disease in the US. *BMC Cardiovasc Disord.* 2024;24(1):543. doi: 10.1186/s12872-024-04225-y. 7. Shaukat Ali A, Finnerty V, Harel F, et al. Impact of rubidium imaging availability on management of patients with acute chest pain. *J Nucl Cardiol.* 2022;29(6):3281-3290. doi: 10.1007/s12350-022-02923-8. 8. Maddahi J, Packard RRS. Cardiac PET perfusion tracers: current status and future directions. *Semin Nucl Med.* 2014;44(5):333-343. 9. Flyrcado (flurpiridaz F 18 injection). Full Prescribing Information. Marlborough, MA: GE Healthcare.



Scan the QR code to view
full Prescribing Information.

© 2026 GE Healthcare. Flyrcado is a trademark of GE Healthcare. GE is a trademark of General Electric Company used under trademark license. February 2026 | JB13040US